title: The pharmacological exploitation of cholesterol 7alpha-hydroxylase, the key enzyme in bile acid synthesis: from binding resins to chromatin remodelling to reduce plasma cholesterol.
abstract: Mammals dispose of cholesterol mainly through 7alpha-hydroxylated bile acids, and the enzyme catalyzing the 7alpha-hydroxylation, cholesterol 7alpha-hydroxylase (CYP7A1), has a deep impact on cholesterol homeostasis. In this review, we present the study of regulation of CYP7A1 as a good exemplification of the extraordinary contribution of molecular biology to the advancement of our understanding of metabolic pathways that has taken place in the last 2 decades. Since the cloning of the gene from different species, experimental evidence has accumulated, indicating that the enzyme is mainly regulated at the transcriptional level and that bile acids are the most important physiological inhibitors of CYP7A1 transcription. Multiple mechanisms are involved in the control of CYP7A1 transcription and a variety of transcription factors and nuclear receptors participate in sophisticated regulatory networks. A higher order of transcriptional regulation, stemming from the so-called histone code, also applies to CYP7A1, and recent findings clearly indicate that chromatin remodelling events have profound effects on its expression. CYP7A1 also acts as a sensor of signals coming from the gut, thus representing another line of defence against the toxic effects of bile acids and a downstream target of agents acting at the intestinal level. From the pharmacological point of view, bile acid binding resins were the first primitive approach targeting the negative feed-back regulation of CYP7A1 to reduce plasma cholesterol. In recent years, new drugs have been designed based on recent discoveries of the regulatory network, thus confirming the position of CYP7A1 as a focus for innovative pharmacological intervention.
authors.affiliation: Dipartimento di Scienze Farmacologiche, Università degli Studi di Milano, Milan, Italy.
authors.forename: Federica
authors.initials: F
authors.lastname: Gilardi
authors.forename: Nico
authors.initials: N
authors.lastname: Mitro
authors.forename: Cristina
authors.initials: C
authors.lastname: Godio
authors.forename: Elena
authors.initials: E
authors.lastname: Scotti
authors.forename: Donatella
authors.initials: D
authors.lastname: Caruso
authors.forename: Maurizio
authors.initials: M
authors.lastname: Crestani
authors.forename: Emma
authors.initials: E
authors.lastname: De Fabiani
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001647:Bile Acids and Salts / Q000378:metabolism*; D002784:Cholesterol / Q000378:metabolism; D002790:Cholesterol 7-alpha-Hydroxylase / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D042002:Chromatin Assembly and Disassembly / Q000187:drug effects*; D002940:Circadian Rhythm; D004032:Diet; D015971:Gene Expression Regulation, Enzymologic; D006706:Homeostasis; D006801:Humans; D007475:Ion Exchange Resins / Q000494:pharmacology*; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology; D015398:Signal Transduction
chemical_list: D000924:Anticholesteremic Agents; D001647:Bile Acids and Salts; D007475:Ion Exchange Resins; D018160:Receptors, Cytoplasmic and Nuclear; D002784:Cholesterol; D002790:Cholesterol 7-alpha-Hydroxylase